Accessibility Menu
Roche Ag logo

Roche Ag(OTC) RHHVF

Market Cap$366.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+660%
5 Year+41%
1 Year+55%
1 Month+16%
$455.00
-1.24%
-5.70Today
Roche Ag last closing stock price
MetricPriceDate
Last closeUSD 460.702026-08-07
Roche Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.85%USD 439.412026-07-31
1 month+15.57%USD 398.622026-07-08
3 month+12.64%USD 409.002026-05-08
Year to date+14.89%USD 401.002025-12-31
1 year+54.52%USD 298.142025-08-07
3 year+69.04%USD 272.532023-08-08
5 year+40.76%USD 327.292021-08-06
Since inception+659.87%USD 60.632003-06-25

Roche Ag Financials at a Glance

Market Cap

$366.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 124.27B

Net Income (TTM)

CHF 21.73B

EPS (TTM)

$19.34

P/E Ratio

23.55

Dividend

$12.41

Beta (Volatility)

0.25 (Low)

Price

$455.00

Volume

145

Open

$467.14

Previous Close

$455.00

Daily Range

$452.18 - $467.14

52-Week Range

$300.15 - $490.33

Estimated Earnings Date

Feb 4, 2027

RHHVF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Roche Ag

Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company is headquartered in Basel, Switzerland, and has a significant presence in key markets such as Germany and the United States.

Products and Services
  • Pharmaceuticals for oncology, neuroscience, and infectious diseases
  • In vitro diagnostic tests for various diseases, including cancer and diabetes
  • Research partnerships focused on innovative treatments, such as inflammatory bowel disease
Growth Outlook
  • Recent quarterly revenue reached CHF 30.19 billion, showcasing strong market demand
  • Net income for Q2 2026 was CHF 6.83 billion, reflecting robust profitability
  • Research and development expenses indicate a commitment to innovation and future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of CHF 120.5 billion, demonstrating consistent performance
  • Net profit margin of 20.25% TTM, indicating effective cost management
  • Dividend yield of 2.72% TTM, appealing for income-focused investors
Roche Holding AG is recognized for its extensive portfolio in pharmaceuticals and diagnostics, addressing critical healthcare needs globally. The company's commitment to research and development is evident in its significant investment in innovative treatments, which positions it well for future growth. Recent financial performance highlights a strong revenue base and profitability, making it an attractive option for potential investors interested in the healthcare sector. The consistent dividend yield further enhances its appeal, providing a steady income stream alongside capital appreciation potential.
AI Generated • Jul 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

112,774

CEO

Thomas Schinecker, PhD

Website

www.roche.com

Headquarters

Basel, 4070, CH

RHHVF Financials

Key Financial Metrics (TTM)

Gross Margin

73.32%

Operating Margin

31.92%

Net Income Margin

20.25%

Return on Equity

37.12%

Return on Capital

23.97%

Return on Assets

12.57%

Earnings Yield

4.25%

Dividend Yield

2.69%

Payout Ratio

72.34%

Stock Overview

Market Cap

$366.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

795.62M

Volume

145

Avg. Volume

4.37K

Financials (TTM)

Gross Profit

CHF 91.13B

Operating Income

CHF 32.57B

EBITDA

CHF 37.39B

Operating Cash Flow

CHF 37.65B

Capital Expenditure

-CHF 8.60B

Free Cash Flow

CHF 29.05B

Cash & ST Invst.

CHF 9.68B

Total Debt

CHF 31.63B

Roche Ag Performance Analysis

Roche Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 66,258,309,430-3.5%
20232023-12-31CHF 65,337,879,703-1.4%
20242024-12-31CHF 68,692,208,3065.1%
20252025-12-31CHF 74,072,268,7687.8%
Roche Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-312.9%
Q22025-06-300.7%
Q42025-12-31-4.0%
Q22026-06-30-1.3%
Roche Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 16.26-8.2%
20232023-12-31CHF 15.91-2.1%
20242024-12-31CHF 11.72-26.4%
20252025-12-31CHF 19.3164.8%
Roche Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-67.7%
Q22025-06-30266.3%
Q42025-12-31-26.1%
Q22026-06-3023.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 30.19B

-1.8%

Gross Profit

CHF 22.26B

-4.4%

Gross Margin

73.72%

N/A

Market Cap

$366.54BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.55M

N/A

Employees

103,249

N/A

Net Income

CHF 6.83B

+9.2%

EBITDA

CHF 9.39B

-14.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 9.68B

+9.8%

Total Debt

CHF 31.63B

-12.6%

Accounts Receivable

CHF 13.27B

+9.0%

Inventory

CHF 8.05B

+1.3%

Long Term Debt

CHF 25.08B

-16.8%

Short Term Debt

CHF 6.55B

+8.7%

Return on Assets

12.57%

N/A

Return on Invested Capital

28.05%

N/A

Free Cash Flow

CHF 5.57B

-10.0%

Operating Cash Flow

CHF 7.13B

-9.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHHBYRoche Holding AG
$57.45+0.33%
RHHBFRoche Holding AG
$461.32+4.29%
NVSNovartis AG
$156.79+0.29%
NVSEFNovartis AG
$151.42-0.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About RHHVF

What is the current price of Roche Ag?

Roche Ag is trading at $455.00 per share.

What is the 52-week range for Roche Ag?

Over the past 52 weeks, Roche Ag has traded between $300.15 and $490.33.

How much debt does Roche Ag have?

As of the most recent reporting period, Roche Ag reported total debt of CHF 41.89B.

How much cash does Roche Ag have on hand?

Roche Ag reported CHF 7.05B in cash and cash equivalents in its most recent financial results.

What is Roche Ag’s dividend yield?

Roche Ag currently has a dividend yield of 2.69%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services